EOLS logo

Evolus Inc. (EOLS)

$6.63

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on EOLS

Market cap

$438828867

EPS

-0.46

P/E ratio

--

Price to sales

1.61

Dividend yield

--

Beta

1.385803

Price on EOLS

Previous close

$6.96

Today's open

$6.90

Day's range

$6.62 - $7.03

52 week range

$3.86 - $9.31

Profile about EOLS

CEO

David Moatazedi

Employees

353

Headquarters

Newport Beach, CA

Exchange

NASDAQ Global Market

Shares outstanding

66188366

Issue type

Common Stock

EOLS industries and sectors

Healthcare

Pharmaceuticals

News on EOLS

Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows

Evolus NASDAQ: EOLS executives said the company expects its expanding lineup of injectable aesthetics products to support growth as it prepares for the anticipated launch of Evolysse Sculpt in 2027.

news source

MarketBeat • Nov 16, 2026

news preview

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during August 2026 to November 2026 of an aggregate of 194,335 restricted stock units (RSUs) of the company's common stock to 25 newly hired non-executive employees. The RSUs vest 25% on each anniversary of the vesting commencement date, subject to each employee's continued service and the terms of t.

news source

Business Wire • Nov 13, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

news source

PRNewsWire • Nov 12, 2026

news preview

What Evolus (EOLS) Said on Its Q3 Earnings Call

Evolus NASDAQ: EOLS reported third-quarter revenue of $78 million, up 13% from a year earlier, as sales of its injectable products grew and the company posted its fourth consecutive quarter of positive adjusted EBITDA.

news source

MarketBeat • Nov 5, 2026

news preview

Evolus, Inc. (EOLS) Q3 2026 Earnings Call Transcript

Evolus, Inc. (EOLS) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the third quarter ended September 30, 2026. “Our third quarter results demonstrate the continued strength of our commercial execution and the progress we are making in building a diversified global performance beauty company,” said David Moatazedi, President and Chief Executive Offic.

news source

Business Wire • Nov 4, 2026

news preview

Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.14 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Evolus to Participate in Upcoming Investor Conferences in New York and London

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will participate in two upcoming investor conferences in New York and London: The Stifel Healthcare Conference, where management will participate in a fireside chat and host investor meetings on Wednesday, November 11, 2026, in New York City. The fireside chat is scheduled for 2:0.

news source

Business Wire • Oct 28, 2026

news preview

Evolus to Report Third Quarter Financial Results on November 4, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the U.S. financial markets close.Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.To p.

news source

Business Wire • Oct 21, 2026

news preview

Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has entered into an option agreement with a privately held company developing a novel, procedure-based, sustained-release injectable treatment for hair restoration.The agreement advances Evolus' business development strategy by adding a potential new category that is complementary to its existing injec.

news source

Business Wire • Oct 14, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Evolus Inc.

Open an M1 investment account to buy and sell Evolus Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in EOLS on M1